DIUCARDIN Drug Patent Profile

Which patents cover Diucardin, and what generic alternatives are available?

Diucardin is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in DIUCARDIN is hydroflumethiazide. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide profile page.

Summary for DIUCARDIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DIUCARDIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	DIUCARDIN	hydroflumethiazide	TABLET;ORAL	083383-001	Approved Prior to Jan 1, 1982		DISCN	No	No

DIUCARDIN (Investment Scenario and Fundamentals Analysis)

Last updated: April 25, 2026

What is DIUCARDIN and how is it positioned commercially?

DIUCARDIN is a pharmaceutical brand name associated with diuretics. Market behavior and investment relevance are driven less by “platform” value and more by dose-form portfolio breadth, reimbursement status, competitive intensity, and patent-driven exclusivity.

Across typical diuretic category dynamics, investment outcomes hinge on three repeatable fundamentals:

• Pricing power: diuretics compete on price and formulary access more than on differentiation.
• Supply and compliance: small manufacturing variances can destabilize continuity of supply.
• Regulatory durability: renewals, inspections, and label consistency govern ability to defend volume.

What does the product’s fundamentals map to in an investor model?

Because DIUCARDIN is a brand-level diuretic exposure, the investor model is best framed around cash flow stability and risk-adjusted exclusivity rather than platform optionality.

Core cash-flow drivers

• Formulary coverage in key markets (tends to determine volume more than marketing spend).
• Competitor mix across loop, thiazide-like, and potassium-sparing segments.
• Substitution risk from generics and private-label equivalents.
• Channel structure (hospital vs retail), which determines tender leverage and working-capital intensity.

Core downside drivers

• Patent cliff / generic erosion: diuretics commonly face accelerated erosion once exclusivity ends.
• Regulatory interruptions: manufacturing noncompliance can stop shipments and trigger payer churn.
• Line extensions: if competitors broaden fixed-dose or improved tolerability options, DIUCARDIN can lose share even before generics arrive.

What does an investment scenario look like for a diuretic brand like DIUCARDIN?

A defensible scenario analysis separates the investment story into three “value gates”:

Gate 1: Exclusivity horizon (or lack of it)

• If DIUCARDIN has meaningful remaining exclusivity: investors underwrite multi-year volume protection and moderate price defense.
• If exclusivity is near-ended or already exhausted: valuation should anchor to generic-proofing (distribution strength, tender ties, and patient stability) and cost leadership.

Gate 2: Volume durability through switching cycles

Diuretic patients often remain on therapy for long periods, but switches still happen due to:

• intolerance,
• electrolyte management,
• prescriber preference,
• insurance policy changes.

Investment implication: DIUCARDIN performance is most sensitive to net retention rate and formulary listing duration.

Gate 3: Margin resilience

For generic-prone categories, margin resilience depends on:

• manufacturing yield and batch consistency,
• procurement and energy inputs,
• packaging and label stability,
• contracting discipline with wholesalers and institutions.

Investment implication: even when revenue declines, profitability can stay stable if supply-chain leverage improves.

What are the key operating metrics investors should track for DIUCARDIN?

DIUCARDIN-specific due diligence should center on measurable operational KPIs that reflect category realities:

Metric	Why it matters	Investor signal
Market share trend by segment	Diuretics split by indication and prescriber behavior	Share stability implies pricing resilience
Tender outcomes / institutional volume	Hospital tenders drive large, lumpy volume	Losing tenders often accelerates erosion
Gross margin and COGS per unit	Manufacturing efficiency and input cost	Margin compression signals competitive pressure
% sales from repeat prescriptions	Captures patient retention	Lower retention increases churn risk
Stock availability and lead times	Supply continuity affects formulary retention	Shortages cause irreversible switching

How does competitive intensity shape expected returns?

Diuretic categories are structurally exposed to:

• multiple manufacturers,
• high therapeutic substitutability, and
• low differentiation outside of dosing convenience and tolerability.

For DIUCARDIN, the competitive landscape typically translates to:

• faster price declines post-generic entry,
• heavier payer pressure,
• increased substitution at pharmacy counter and institutional formularies.

Investment implication: the only durable edge usually comes from contracting strength (tender terms), distribution reach, and consistent supply.

What does pipeline and patent risk mean for DIUCARDIN valuation?

For a brand-level diuretic exposure, “pipeline” is usually secondary to:

• patent/exclusivity life for the active and formulation,
• regulatory exclusivity for specific dosage forms, and
• line extensions that delay full commoditization.

Valuation sensitivity

• If remaining exclusivity is short: valuation should discount aggressively for market share decline and pricing compression.
• If exclusivity is meaningful: valuation can include a longer period of stable gross margin assuming supply remains consistent.

What are the scenario outcomes investors should underwrite?

A practical underwriting framework uses three cases tied to exclusivity and share dynamics.

1) Base case (moderate erosion)

• Formulary position remains intact.
• Price declines gradually post intensified competition.
• Margins hold via cost controls and stable supply.

2) Downside case (accelerated erosion)

• Tender losses and rapid generic substitution.
• Higher working-capital strain due to channel volatility.
• Gross margin compresses due to competitive pricing and lower scale utilization.

3) Upside case (extended durability)

• DIUCARDIN holds share through prescriber retention and institutional contracting.
• Line extensions or dose-form improvements protect differentiation longer than peers.
• Cost advantage sustains margin while revenue declines slower than category average.

What fundamentals support or weaken DIUCARDIN’s investment case?

DIUCARDIN’s fundamentals should be judged through two lenses: defense of volume and control of margin.

Supports

• Stable patient base in chronic indications.
• Strong institutional or payer contracting.
• Manufacturing reliability that preserves distribution confidence.
• Active cost optimization and scale utilization.

Weakens

• Increasing price transparency enabling payer substitution.
• Loss of key formulary access.
• Margin drag from input cost inflation without offsetting price.
• Quality incidents that reduce shipment continuity.

What diligence actions determine whether the thesis is investable?

For a diuretic brand, diligence is not about clinical novelty. It is about the mechanics of revenue defense.

Diligence item	Investment relevance	What “good” looks like
Formulary and reimbursement mapping	Predicts durable volume	Listed status in top channels with minimal disruptions
Tender and contracting terms	Drives institutional volume	Multi-year agreements or favorable pricing cadence
Manufacturing inspection and batch record stability	Predicts continuity	No recurring deviations affecting release timelines
Competitive pricing track	Predicts revenue compression	Competitive parity without persistent undercutting
Brand vs generic mix	Predicts share loss speed	Slow shift from branded to generic equivalents

Key Takeaways

• DIUCARDIN is a diuretic-exposed brand where investment returns depend primarily on formulary durability, contracting strength, and margin control, not platform differentiation.
• The valuation should be structured around exclusivity horizon and share erosion speed, with scenarios tied to tender outcomes, substitution risk, and supply continuity.
• Investors should underwrite cash-flow stability through measurable KPIs: share trend, institutional volume, gross margin resilience, repeat prescription rates, and stock availability.

FAQs

1) Is DIUCARDIN a high-growth investment?

DIUCARDIN fits a category where growth is typically constrained once commoditization accelerates. The more investable pattern is stable cash flow with controlled margin decline.

2) What is the dominant risk for a diuretic brand thesis?

The dominant risk is generic substitution and contracting pressure, which can compress pricing and trigger volume loss faster than expected.

3) How should investors value DIUCARDIN?

Value DIUCARDIN using scenario-based cash flow anchored to exclusivity (if any) and a modeled rate of price and share erosion, plus manufacturing-driven margin durability.

4) What operational factor most influences revenue continuity?

Supply continuity and packaging/label consistency influence whether payers and institutions maintain placement, which directly affects volume.

5) What signals early that the downside case is unfolding?

Rising tender losses, faster market share decline, and persistent gross margin compression are the clearest leading indicators.

---

References

[1] APA citation placeholder (no sources were provided with the request).